A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Published:2015-09 Issue:3 Volume:138 Page:507-512
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Bender David,Sill Michael W.,Lankes Heather A.,Reyes Henry D.,Darus Christopher J.,Delmore James E.,Rotmensch Jacob,Gray Heidi J.,Mannel Robert S.,Schilder Jeanne M.,Hunter Mark I.,McCourt Carolyn K.,Samuelson Megan I.,Leslie Kimberly K.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference28 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J. Clin.,2013

2. Cancer Facts and Figures,2011

3. SEER Cancer Statistics Review;Howlader,2013

4. Abstract: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Miller;Gynecol. Oncol.,2012

5. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study;Aghajanian;J. Clin. Oncol.,2011

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locally advanced and metastatic endometrial cancer: Current and emerging therapies;Cancer Treatment Reviews;2024-09

2. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer;Cancer;2023-12-21

3. Complete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case;Surgery and Oncology;2023-12-21

4. Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets;The Journal of Steroid Biochemistry and Molecular Biology;2023-11

5. The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review;Life;2023-07-03